


# State of biotech sector—2004

Stacy Lawrence

In its latest annual review of the biotech industry, business consulting firm Ernst & Young finds a sector in flux (for 2003 stats see *Nat. Biotechnol.* 22, 789, 2004). Profitability still looks distant; although revenues for public companies were up by 17%, so were net losses.

## Top ten countries by number of companies


Several major European countries as well as the US saw the overall number of biotech companies decline last year; Australia and Israel show healthy growth.



Source: Ernst & Young

## Employees of public biotech companies


Whereas biotech employment shrank in Europe last year (by >20%), US and Asian employment grew significantly (by 10% and 37%, respectively).



Source: Ernst & Young

## Global biotech revenue and spending

Outside Europe, average revenue of biotechs shows fast growth. On the other hand, European biotechs are best rationing R&D spend.




Source: Ernst & Young

Employment was up in the US and in Asia, but plummeted (down 21%) in Europe; the number of private companies contracted significantly in both the US and Europe, whereas Asia showed strong growth.

## Number of biotech companies

Globally, public companies grew by 5% (from 611 to 641), whereas private enterprises declined by 2% (3,860 to 3,775), particularly in the US and Europe.



Source: Ernst & Young

## Capital concentration in Western public biotechs

US biotech is best capitalized, most European companies have more than a year of cash, but over a third of Canadian firms are low on funding



Source: Ernst & Young

## Global overview of biotech companies

Public company data	2003	2004	Percent change (%)
Revenues (millions)	\$46,553	\$54,613	17
R&D expense (millions)	\$18,636	\$20,888	12
Net loss (millions)	\$4,548	\$5,304	17
Number of employees	174,520	183,820	5

Source: Ernst & Young